Author details

Full Name

James E Korkola

Affiliation

ORCID

Career Start Year

1997

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37935340	Functional delineation of the luminal epithelial microenvironment in breast using cell-based screening in combinatorial microenvironments.	Cell Signal	2024
36547263	An altered extracellular matrix-integrin interface contributes to Huntington's disease-associated CNS dysfunction in glial and vascular cells.	Hum Mol Genet	2023
37384294	Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.	Front Oncol	2023
35262628	Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.	J Exp Med	2022
36233691	Urinary Comprehensive Genomic Profiling Correlates Urothelial Carcinoma Mutations with Clinical Risk and Efficacy of Intervention.	J Clin Med	2022
36207580	A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses.	Commun Biol	2022
36063034	Systematic replication enables normalization of high-throughput imaging assays.	Bioinformatics	2022
35788566	A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.	Nat Biotechnol	2022
35248133	INHBA is a mediator of aggressive tumor behavior in HER2+â¿¿basal breast cancer.	Breast Cancer Res	2022
32981205	Cellular senescence in cancer: from mechanisms to detection.	Molecular Oncology	2021
34344439	Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.	Breast Cancer Res	2021
34531645	Automatic Transformation and Integration to Improve Visualization and Discovery of Latent Effects in Imaging Data.	J Comput Graph Stat	2020
33303959	Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.	Sci Rep	2020
33070041	Crosstalk between invadopodia and the extracellular matrix.	Eur J Cell Biol	2020
32904984	Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized drug sensitivity and survival.	Neurooncol Adv	2020
30846826	Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.	Sci Rep	2019
31675914	Annot: a Django-based sample, reagent, and experiment metadata tracking system.	BMC Bioinformatics	2019
30650355	Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting.	Cell Rep	2019
31302153	A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines.	Cell Syst	2019
31180341	Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer.	J Vis Exp	2019
29199020	The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations.	Cell Syst	2018
30214939	Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival.	Sci Adv	2018
29942081	Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.	Nat Chem Biol	2018
29358169	CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.	Cancer Res	2018
29550255	Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.	Cell Syst	2018
28183333	Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.	Breast Cancer Res	2017
29020035	Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.	PLoS One	2017
29112189	Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics.	Sci Data	2017
28017544	Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling.	Cell Syst	2017
27132888	Mechanism and Role of SOX2 Repression in Seminoma: Relevance to Human Germline Specification.	Stem Cell Reports	2016
27368372	Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.	Breast Cancer Res	2016
27276681	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.	Oncotarget	2016
26624623	Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach.	PLoS One	2015
25336442	Interrogation of a context-specific transcription factor network identifies novel regulators of pluripotency.	Stem Cells	2015
25901353	Disentangling multidimensional spatio-temporal data into their common and aberrant responses.	PLoS One	2015
25962591	Erratum to: Modeling precision treatment of breast cancer.	Genome Biol	2015
26317216	Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.	PLoS One	2015
26181325	Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.	PLoS One	2015
25161235	Causal network inference using biochemical kinetics.	Bioinformatics	2014
24176112	Modeling precision treatment of breast cancer.	Genome Biol	2013
27605183	Expanding the Diversity of Imaging-Based RNAi Screen Applications Using Cell Spot Microarrays.	Microarrays (Basel)	2013
23929892	Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay.	Mol Cell Proteomics	2013
22003129	Subtype and pathway specific responses to anticancer compounds in breast cancer.	Proc Natl Acad Sci U S A	2012
22628411	A central role for RAFâ¿¿MEKâ¿¿ERK signaling in the genesis of pancreatic ductal adenocarcinoma.	Cancer Discov	2012
22875744	Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.	Breast Cancer Res Treat	2012
22728437	The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.	Cancer Discov	2012
19911427	A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells.	Stem Cells	2010
20060285	Breast cancer genomes--form and function.	Curr Opin Genet Dev	2010
19840009	Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin.	BJU International	2009
19396148	Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas.	Mod Pathol	2009